Clinical Trial Update: Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating GSK2879552 alone or with azacitidine in high-risk myelodysplastic syndromes; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• GSK2879552

Snippet

Sponsor: GlaxoSmithKline | Conditions: Myelodysplastic Syndrome, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-05-14